State of New Jersey Common Pension Fund D Lowers Holdings in Prestige Consumer Healthcare Inc. $PBH

State of New Jersey Common Pension Fund D lowered its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 48.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,798 shares of the company’s stock after selling 15,701 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Prestige Consumer Healthcare were worth $1,036,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Bayforest Capital Ltd bought a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $29,000. First Horizon Corp bought a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the last quarter. Torren Management LLC purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth $35,000. Finally, Danske Bank A S purchased a new position in shares of Prestige Consumer Healthcare in the third quarter worth $37,000. Institutional investors own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PBH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Jefferies Financial Group dropped their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Finally, Oppenheimer cut their price objective on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $74.75.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $50.53 on Tuesday. Prestige Consumer Healthcare Inc. has a 52-week low of $49.28 and a 52-week high of $89.37. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The firm’s fifty day moving average is $59.50 and its 200 day moving average is $61.77. The company has a market cap of $2.39 billion, a price-to-earnings ratio of 13.37, a PEG ratio of 1.57 and a beta of 0.40.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 2,553 shares of company stock worth $151,444. 1.40% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).